Abstract
Aims:
This study intended to examine correlations between interleukin 6 serum levels, blood group, and underlying disease in patients admitted to the COVID-19 intensive care unit.
Background:
Understanding the relationship between a patient's blood group, underlying disease(s), and the body's cytokine reactions is essential for care provision to COVID-19 patients.
Materials and Methods:
The clinical records of 31 patients admitted to an intensive care unit were analyzed using a census method. Data were collected using a researcher-developed checklist and analyzed with SPSS-22 statistical software using one-way analysis of variance and Tukey-Kramer post hoc, independent t, and multiple regression. The level of significance was set to p <0.05.
Results:
The mean serum level of interleukin 6 was significantly higher in patients with blood type B and those with two or more underlying diseases (p <0.05). The mean serum interleukin 6 levels in patients differed significantly based on the history of COVID-19 vaccine injection and the length of hospitalization (p <0.05). The mean serum interleukin 6 levels were associated with the length of COVID-19 intensive care unit stay and survival (p <0.05).
Conclusion:
Effective and timely care provision for COVID-19 patients is a top priority, which can be achieved by understanding the correlation between the body's cytokine reactions in the fight against COVID-19, blood type, and underlying diseases.
Publisher
Bentham Science Publishers Ltd.
Subject
Public Health, Environmental and Occupational Health,Community and Home Care,Health (social science)
Reference48 articles.
1. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR.
Global epidemiology of coronavirus disease 2019 (COVID-19): Disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status.
Int J Antimicrob Agents
2020;
55
(4)
: 105946.
2. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS.
SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options.
Eur Rev Med Pharmacol Sci
2020;
24
(7)
: 4016-26.
3. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.
Int J Antimicrob Agents
2020;
55
(3)
: 105924.
4. Wu C, Liu Y, Yang Y, et al.
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.
Acta Pharm Sin B
2020;
10
(5)
: 766-88.
5. Patel S, Saxena B, Mehta P.
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Heliyon
2021;
7
(2)
: e06158.